Company Overview and News

0
IHH Healthcare confident about its move into India

2018-07-16 theedgemarkets
KUALA LUMPUR: IHH Healthcare Bhd said it is confident in its move to expand its footprint in India, following the acceptance of its bid to acquire a controlling stake in Fortis Healthcare Ltd.
5225 FORTIS 6888 532915 RELIGARE AXXTF FORTISMLR Q0F IHHHF 532843 523696

0
Religare Enterprises Limited - News Clarification

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Religare Enterprises Limited - News Clarification

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Brothers Singh and the squandering of a business empire

2018-07-10 livemint
Mumbai/New Delhi: “But, how could they...? I mean how did they manage to bring down such a massive business empire,” a Delhi-based industrialist said, when asked about how the Delhi business club views the decline of the Singh brothers—Malvinder Singh and Shivinder Singh of Fortis Healthcare Ltd.
532454 RF1U FORTIS RLGHY 532915 RLGHF RELIGARE BHRQY BHARTIARTL 532843

0
Religare Enterprises Limited - Resignation

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Religare Enterprises Limited - Updates

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
LVB shares hit 3-week low

2018-06-28 thehindubusinessline
Shares of Lakshmi Vilas Bank today hit a 3-week low as SEBI has questioned the firm regarding a tiff with Religare tiff. The stock dropped as much as 5.9 per cent to Rs 104.1, its lowest since June 6. The stock posted biggest intraday percentage loss since June 6.
LAKSHVILAS 534690 532915 RELIGARE

0
Fortis defers financial results again, board meeting today

2018-06-26 livemint
New Delhi: Newly-appointed board of Fortis Healthcare Ltd, which is in the process of finding an investor, has again deferred approval of quarterly and annual financial results for the period ended 31 March, saying the issue requires more deliberation. The board, which met on 25 June for considering results, will reconvene on Tuesday.
FORTIS 532915 RELIGARE 532843

0
Religare Enterprises Limited - Credit Rating

2018-06-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Religare Enterprises says LVB action on RFL deposits illegal

2018-06-13 moneycontrol
Religare Enterprises on Wednesday said its subsidiary Religare Finvest never created any security over its deposits of Rs 794 crore with Lakshmi Vilas Bank, which the lender has held against loan defaults by third parties RHC Holding and Ranchem Pvt Ltd.
LAKSHVILAS FORTIS 534690 532915 RELIGARE 532843

0
Religare Enterprises Limited - Updates

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Religare Enterprises Limited - Resignation

2018-06-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532915 RELIGARE

0
Company news: Religare Enterprises

2018-06-04 thehindubusinessline
Religare Enterprises, a diversified financial services group, has announced the appointment of Malay Kumar Sinha as Non-Executive Independent Director on its board. As an Indian Police Service officer, Sinha has served in various capacities in the Uttar Pradesh Police, Intelligence Bureau and the Ministry of Home Affairs, Government of India. Thereafter, he worked as Joint Secretary in the Ministry of External Affairs and finally as Secretary-Security, Cabinet Secretariat, Rashtrapati Bhawan.
PNJZY 532461 532915 RELIGARE PNB

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

9h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...